CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from 10 brokerages (9 buys, 1 sell) with an average 1‑year price target of $13.44 and several firms (including Jefferies and Barclays) recently raising targets up to $16.
• The company missed the quarter with EPS of ($0.22) vs. ($0.08) expected and revenue of $0.66M vs. $7.33M consensus, and shows negative ROE/net margin and a negative P/E (-114).
• Insiders have been selling stock (191,063 shares worth about $1.23M in the last 90 days, including March 17 sales), while institutional ownership is high at roughly 67.8%.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.4444.

Several research analysts have weighed in on the company. Piper Sandler boosted their price target on CytomX Therapeutics from $10.00 to $12.00 and gave the stock an "overweight" rating in a research report on Monday, March 23rd. Cantor Fitzgerald increased their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an "overweight" rating in a report on Wednesday, February 4th. Wedbush raised their target price on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an "outperform" rating in a research note on Tuesday, March 17th. Jefferies Financial Group boosted their target price on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the stock a "buy" rating in a report on Wednesday, March 18th. Finally, Barclays upped their price target on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, March 19th.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $4.56 on Friday. The business has a 50-day moving average of $5.18 and a 200-day moving average of $4.30. The stock has a market capitalization of $776.05 million, a price-to-earnings ratio of -114.00 and a beta of 2.49. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. On average, sell-side analysts expect that CytomX Therapeutics will post -0.05 EPS for the current year.

Insider Activity

In related news, insider Yu-Waye Chu sold 21,279 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $136,611.18. Following the completion of the sale, the insider directly owned 189,446 shares in the company, valued at approximately $1,216,243.32. This trade represents a 10.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christopher Ogden sold 19,323 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the transaction, the chief financial officer owned 296,948 shares of the company's stock, valued at $1,906,406.16. The trade was a 6.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 191,063 shares of company stock valued at $1,226,624 in the last 90 days. 6.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC bought a new stake in CytomX Therapeutics in the 4th quarter valued at $52,000. Seven Fleet Capital Management LP bought a new position in CytomX Therapeutics during the fourth quarter worth $208,000. Empowered Funds LLC acquired a new position in shares of CytomX Therapeutics in the fourth quarter valued at $133,000. XTX Topco Ltd increased its holdings in shares of CytomX Therapeutics by 63.9% in the fourth quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 18,705 shares during the last quarter. Finally, Virtus Investment Advisers LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at about $270,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.